Clinicians often face a significant dilemma when managing patients with culture-negative sepsis. While broad-spectrum therapy is life-saving during the initial phase, prolonged use contributes heavily to antimicrobial resistance. A recent study published in the Journal of Critical Care explores the impact of antibiotic de-escalation in sepsis on patient outcomes. Researchers specifically investigated whether reducing the intensity of therapy influences 30-day mortality rates in this specific population.

The Duke Health System Study Overview

This retrospective cohort study analyzed data from over 7,700 adult patients treated within the Duke Health System between 2016 and 2023. These patients presented with community-onset sepsis but had negative bacterial cultures. To maintain diagnostic accuracy, the researchers utilized the CDC Adult Sepsis Event criteria. They also stratified patients based on changes in their Sequential Organ Failure Assessment (SOFA) scores over the first three days of care.

Furthermore, the team defined de-escalation as a reduction in antibiotic rank, discontinuation of anti-MRSA agents, or a decrease in the total number of antibiotics within five days of onset. Consequently, they could evaluate the safety of narrowing therapy even when the causative pathogen remained unidentified. This methodology allowed for a robust assessment of real-world stewardship practices.

Safety of Antibiotic De-escalation in Sepsis

The results provide significant reassurance for hospital antimicrobial stewardship programs. Approximately 62% of the study participants underwent antibiotic de-escalation during their treatment. Most importantly, the multivariable regression analysis revealed no significant association between de-escalation and 30-day mortality. The adjusted odds ratio stood at 0.92, indicating that narrowing therapy did not compromise patient survival.

Additionally, the findings remained consistent across different clinical trajectories. Whether a patient's SOFA score improved, remained stable, or deteriorated, de-escalation did not lead to worse outcomes. Therefore, clinicians can confidently prioritize stewardship efforts without fearing an increase in mortality risk. This evidence suggests that clinical stability is a reliable guide for therapy adjustments.

Clinical Implications for Practice

Managing culture-negative sepsis requires a delicate balance between aggressive treatment and avoiding antibiotic overuse. This research highlights that two-thirds of patients already undergo de-escalation safely. Moreover, it suggests that there is still room to optimize therapy in the remaining third of the population. By focusing on clinical improvement rather than waiting for positive cultures, medical teams can reduce the burden of broad-spectrum antibiotics and minimize potential side effects.

Frequently Asked Questions

Does antibiotic de-escalation increase mortality in culture-negative sepsis?

No, this study found no association between de-escalation and increased 30-day mortality. The survival rates were comparable between those who continued broad-spectrum therapy and those who had their antibiotics narrowed.

How was de-escalation defined in this research?

De-escalation included reducing the antibiotic rank across four spectrum-based categories, stopping anti-MRSA medications, or reducing the total number of prescribed antibiotics within five days.

Is de-escalation safe for patients whose condition is not improving?

Yes, the researchers observed similar mortality outcomes across all SOFA change strata. This includes patients whose condition improved, stayed the same, or showed signs of deterioration.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship between the reader and the author. It should not be used as a substitute for professional diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

Ohnuma T et al. Antibiotic De-escalation and 30-day mortality in patients with suspected bacterial culture-negative Sepsis. J Crit Care. 2026 Jun 01. doi: undefined. PMID: 42224805.

Singer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–810.

Evans L, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Intensive Care Med. 2021;47(11):1181-1247.